Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix versus Gardasil cross-neutralization mechanism study in twin girls
2013-002340-90Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Jun 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of human papillomavirus type 16 L1 capsid protein antigen and qHPV vaccine in human papillomavirus infection (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Safety follow-up call. Started Jun 2013; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigenqHPV vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2013-002340-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002340-90.